Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.40 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958636 | 0.84 | CYP2A6 (0.43) | CYP19A1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16348018 | 0.84 | CYP11B1 (0.50) | MAPTCYP11B1CYP11B2SIGMAR1LMNA | |
| SCHEMBL958957 | 0.81 | RAB9A (0.45) | CYP19A1L3MBTL1POLBMAPTCYP11B1 | |
| SCHEMBL11031678 | 0.80 | CYP11B1 (0.50) | L3MBTL1CYP1A2CYP2D6CYP11B1LMNA | |
| SCHEMBL16347306 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6813771 | 0.79 | ENPP2 (0.42) | CYP1A2CYP3A4MAPTLMNAKDM4E | |
| SCHEMBL957615 | 0.77 | KMT2A (0.49) | L3MBTL1POLBMAPTSIGMAR1LMNA | |
| SCHEMBL959163 | 0.77 | KDM4E (0.50) | CYP19A1L3MBTL1MAPTSIGMAR1LMNA | |
| SCHEMBL958758 | 0.77 | CYP19A1 (0.55) | CYP19A1CYP11B1CYP11B2HDAC8HDAC6 | |
| SCHEMBL2699902 | 0.76 | CYP19A1 (0.52) | CYP19A1L3MBTL1CYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | claimed |
| EP-3612522-A1 | THERAPEUTIC COMPOUNDS | Celgene Quanticel Research, Inc. (US) | 2020-02-26 | — | — | EP | claimed |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | claimed |
| WO-2018195155-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-25 | — | — | WO | claimed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | claimed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | claimed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | claimed |
| CN-104755478-B | Serine/threonine kinase inhibitor | 霍夫曼-拉罗奇有限公司 | 2017-10-10 | — | — | CN | claimed |
| WO-2017034377-A1 | PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A ST CO., LTD. (KR) | 2017-03-02 | — | — | WO | claimed |
| US-20170057955-A1 | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-03-02 | — | — | US | claimed |
| WO-2006069097-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | ARGENTA DISCOVERY LIMITED | 2006-06-08 | — | — | US | claimed |
| CN-1684957-A | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | ARGENTA DISCOVERY LTD (GB) | 2005-10-19 | — | — | CN | claimed |
| EP-1525199-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | Argenta Discovery Limited (GB) | 2005-04-27 | — | — | EP | claimed |
| EP-1131331-B1 | 13-MEMBERED AZALIDES AND THEIR USE AS ANTIBIOTIC AGENTS | PFIZER PROD INC (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | claimed |
| CN-1326460-A | Trideca-tertiary azalides and their use as antibiotics | PFIZER PROD INC (US) | 2001-12-12 | — | — | CN | claimed |
| US-6329345-B1 | 13-membered azalides and their use as antibiotic agents | PFIZER INC | 2001-12-11 | — | — | US | claimed |
| EP-1131331-A1 | 13-MEMBERED AZALIDES AND THEIR USE AS ANTIBIOTIC AGENTS | Pfizer Products Inc. (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2000031097-A1 | 13-MEMBERED AZALIDES AND THEIR USE AS ANTIBIOTIC AGENTS | PFIZER PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | CYP19A1 937/4885L3MBTL1 4262/4885CYP1A2 3589/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | CYP19A1 937/4885L3MBTL1 4262/4885CYP1A2 3589/4885 |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | CYP19A1 4420/4885L3MBTL1 868/4885CYP1A2 4769/4885 |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | HDAC1, HDAC11, HDAC2 | CYP19A1 1066/4885L3MBTL1 1353/4885CYP1A2 1750/4885 |
| US-20170057955-A1 | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | KDM1B, KDM1A, KDM3B | CYP19A1 1087/4885L3MBTL1 1804/4885CYP1A2 1523/4885 |
| US-10617680-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | CYP19A1 4420/4885L3MBTL1 868/4885CYP1A2 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.